Bulk Inquiry
NDMC101
- HS-Cm
- Soluble in 0.1N NaOH(aq) and DMSO
- MF: C13H9ClFNO2
- MW: 265.67
Description
NDMC101 exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. NDMC101 is also an osteoclastogenesis inhibitor for experimental arthritis. Its efficacy is associated with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.
More Information
| Parent CAS No. | 1308631-40-4 |
|---|---|
| Chemical Name | N-(4-Chloro-2-fluorophenyl)-2-hydroxybenzamide |
| SMILES | C1C=C(C(=O)NC2C=CC(Cl)=CC=2F)C(O)=CC=1 |
| MFCD | MFCD13200880 |
| InChi | InChI=1S/C13H9ClFNO2/c14-8-5-6-11(10(15)7-8)16-13(18)9-3-1-2-4-12(9)17/h1-7,17H,(H,16,18) |
| InChiKey | NUQWCDAXACRITO-UHFFFAOYSA-N |
| CID | 60202556 |
| Short Description | DPP-4 inhibitor |
References
- CP Cheng et al. A benzamide-linked small molecule NDMC101 inhibits NFATc1 and NF-κB activity: a potential osteoclastogenesis inhibitor for experimental arthritis. J Clin Immunol. 2012 Aug;32(4):762-77.
- JT Liou et al. A salicylate-based small molecule HS-Cm exhibits immunomodulatory effects and inhibits dipeptidyl peptidase-IV activity in human T cells. Eur J Pharmacol. 2014 Mar 5;726:124-32.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 4464 | UAMC-1110 |
From $154.00 |
| 1631 | Vildagliptin |
From $66.00 |
| 2354 | Linagliptin |
From $99.00 |
| 2470 | Trelagliptin succinate |
From $159.50 |
| 3251 | Sitagliptin |
From $55.00 |
| 3309 | Teneligliptin hydrobromide |
From $55.00 |
| 3310 | Alogliptin benzoate |
From $71.50 |
| 3909 | NFATc1 inhibitor A04 |
From $99.00 |
